PARP1 and colonic neoplasm: These findings not only further illuminate our understanding of the signaling and DNA repair pathways that are important in these cells, they also reveal that colon tumor cells are sensitized to FdUrd by small molecule PARP inhibitors that are currently in clinical trials, thus suggesting a novel therapeutic approach that combines FdUrd, a drug approved for the treatment of colon cancer, with a PARP inhibitor, an emerging class of agents with exciting anticancer activity.